Spurious hyperphosphatemia in a patient with alteplase-locked central venous catheter.


Autoria(s): Cachat, F.; Bardy, D.; Durussel, C.; Di Paolo, E.
Data(s)

2006

Resumo

Alteplase has been shown to be effective in preventing central venous access clotting in patients on hemodialysis. Because of a high phosphorus content in its excipient, it can inadvertently contaminate blood samples, leading the physician in care of the patient to erroneously increase dialysis time or change diet in order to control the pseudo-hyperphosphatemia.

Identificador

https://serval.unil.ch/notice/serval:BIB_9FEAE9F52639

info:pmid:16328539

pmid:16328539

doi:10.1007/s00467-005-2088-1

isiid:000234603500030

Idioma(s)

eng

Fonte

Pediatric Nephrology212301-302

Palavras-Chave #Catheterization, Central Venous/instrumentation; Child, Preschool; Fibrinolytic Agents/adverse effects; Humans; Male; Phosphorus Metabolism Disorders/chemically induced; Renal Dialysis/instrumentation; Tissue Plasminogen Activator/adverse effects
Tipo

info:eu-repo/semantics/article

article